The product can induce immunity against hepatitis A virus in recipients following immunization.
Dosage Form
Freeze-dried
Specifications
1.0ml per container after dissolution again. Each single human dose is 1.0ml containing not less than 6.5 Lg CCID50 of live hepatitis A virus.
Eligible
Susceptible persons who older than 18 months
Packaging
Vial.
Storage & Shipping
Store and ship at 2-8°C, protected from light.
Validity Period
18 months
Contraindications
The vaccine shall not be administered to the subjects with discomfort, body temperature (subaxillary) over 37.5°C.
The vaccine shall not be administered to the subjects with acute infectious disease or other serious disease.
The vaccine shall not be administered to the subjects with immunodeficiency or receiving immunosuppressant.
The vaccine shall not be administered to the subjects with a history of anaphylaxis.
Adverse reactions & Treatment
A small number of individuals might have mild fever, pain, redness and swelling at the site of inoculation, which generally could be relieved spontaneously within 72 hours. Occasionally skin rashes may appear and no special treatment is necessary. Symptomatic treatment might be helpful in case of need.
Precautions
Disinfectant shall be prevented from contacting the product during opening the container and the course of injection.
Do not use the vaccine, if any leakage of container, foreign matters, or turbidity of content is found.
The vaccination can only be given at least 30 days after the administration of immunoglobulin.
Women is pregnancy should use the vaccine with caution.
The product is attenuated live vaccine, its not recommended to use during hepatitis A epidemic.
Dosage Form
Freeze-dried
Specifications
1.0ml per container after dissolution again. Each single human dose is 1.0ml containing not less than 6.5 Lg CCID50 of live hepatitis A virus.
Eligible
Susceptible persons who older than 18 months
Packaging
Vial.
Storage & Shipping
Store and ship at 2-8°C, protected from light.
Validity Period
18 months
Contraindications
The vaccine shall not be administered to the subjects with discomfort, body temperature (subaxillary) over 37.5°C.
The vaccine shall not be administered to the subjects with acute infectious disease or other serious disease.
The vaccine shall not be administered to the subjects with immunodeficiency or receiving immunosuppressant.
The vaccine shall not be administered to the subjects with a history of anaphylaxis.
Adverse reactions & Treatment
A small number of individuals might have mild fever, pain, redness and swelling at the site of inoculation, which generally could be relieved spontaneously within 72 hours. Occasionally skin rashes may appear and no special treatment is necessary. Symptomatic treatment might be helpful in case of need.
Precautions
Disinfectant shall be prevented from contacting the product during opening the container and the course of injection.
Do not use the vaccine, if any leakage of container, foreign matters, or turbidity of content is found.
The vaccination can only be given at least 30 days after the administration of immunoglobulin.
Women is pregnancy should use the vaccine with caution.
The product is attenuated live vaccine, its not recommended to use during hepatitis A epidem
